Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis

Aggregate data model‐based meta‐analysis is a regression approach to compare the dose–response and/or time‐course across different treatments using summary level data from the literature. Literature search and systematic review following the Cochrane approach yielded 912 sources for investigational and approved treatments for psoriasis. In addition, data for tofacitinib were obtained from an internal database. Tofacitinib is an oral Janus kinase inhibitor. Two mathematical models were developed for Psoriasis Area and Severity Index (PASI) response in moderate to severe psoriasis patients to quantify the time to maximum effect for PASI75 and to evaluate the dose–response relationship for PASI responders (PASI50, PASI75, PASI90, PASI100) at Week 12. Body weight exhibited an inverse effect on the placebo component of both models, suggesting that body weight affects the overall PASI response regardless of drug. This analysis provides a quantitative framework for efficacy comparisons across psoriasis treatments.

• Publication year

  2017

• Venue

  Clinical pharmacology and therapy

• Publication date

  2017-06-21

• Fields of study

  Mathematics, Medicine

• Identifiers
  DOI 10.1002/cpt.732PMID 28480503PMCID 5697570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Section 6

  2019cited by this paper
• Statins use and risk of dementia

  2018cited by this paper
• Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

  2017cited by this paper
• Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers

  2017cited by this paper
• Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  2017cited by this paper
• Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma

  2017cited by this paper
• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

  2017cited by this paper
• Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs

  2016cited by this paper
• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

  2016cited by this paper
• Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

  2016cited by this paper
• Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL‐2 Inhibitor: Results of a Single‐ and Multiple‐Dose Study

  2016cited by this paper
• Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

  2016cited by this paper
• Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

  2016cited by this paper
• Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 Inhibitor

  2016cited by this paper
• Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

  2016cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

  2016cited by this paper
• Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

  2015cited by this paper
• Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

  2015cited by this paper
• Treatment goals for psoriasis: Should PASI 90 become the standard of care?

  2015cited by this paper
• Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example

  2015cited by this paper
• Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities

  2015cited by this paper
• Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials

  2015cited by this paper
• Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial

  2015cited by this paper
• Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

  2015cited by this paper
• Optimizing Dosing of Oncology Drugs

  2014cited by this paper
• Efficacy of biologics in the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis of randomized controlled trials with different time points

  2014cited by this paper
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

  2014cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  2013cited by this paper
• Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

  2013cited by this paper
• Apoptosis therapy: driving cancers down the road to ruin

  2013cited by this paper
• An historic perspective of proteasome inhibition.

  2012cited by this paper
• Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registry

  2012cited by this paper
• Bortezomib combination therapy in multiple myeloma.

  2012cited by this paper
• Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

  2011cited by this paper
• Unmet supportive care needs, psychological well‐being and quality of life in patients living with multiple myeloma and their partners

  2011cited by this paper
• Benefit–risk assessment: the use of clinical utility index

  2010cited by this paper
• Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation

  2010cited by this paper
• Constitutive neutrophil apoptosis: Mechanisms and regulation

  2008cited by this paper
• Chapter 5: Defining the review question and developing criteria for including studies

  2008cited by this paper
• Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions.

  2003cited by this paper
• The Bcl-2 family: roles in cell survival and oncogenesis

  2003cited by this paper
• The Bcl-2-regulated apoptotic pathway

  2003cited by this paper
• Bias due to aggregation of individual covariates in the Cox regression model.

  2003cited by this paper
• A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis.

  2002cited by this paper
• BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells.

  1992cited by this paper
• Psoriasis

  1906cited by this paper
• A Randomized Controlled Trial

  year unknowncited by this paper

• Partial Residual Plots as an Integrated Model Diagnostic Tool in Model‐Based Meta‐Analysis

  2024cites this paper
• JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review

  2023cites this paper
• Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials

  2023cites this paper
• VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures

  2022cites this paper
• Applications of Model-Based Meta-Analysis in Drug Development

  2022cites this paper
• Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis

  2022cites this paper
• Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.

  2022cites this paper
• Efficacy and Safety of Tofacitinib vs Methotrexate in Patients with Moderate to Severe Plaque Psoriasis

  2021cites this paper
• Color and Texture Prior Based Segmentation and Analysis of Psoriatic Disease Types Using MPSO

  2021cites this paper
• Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules

  2021influential citation
• Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure

  2020cites this paper
• Comparative Efficacy of Drugs for the Treatment of Chronic Constipation

  2020cites this paper
• The response‐time relationship and covariate effects of acupuncture for chronic pain: A systematic review and model‐based longitudinal meta‐analysis

  2020cites this paper
• Meta-analysis and Indirect Comparisons: On Methods, Paradigms, and Biologic Treatments for Psoriasis.

  2020cites this paper
• Model‐Based Meta‐Analysis in Ankylosing Spondylitis: A Quantitative Comparison of Biologics and Small Targeted Molecules

  2019cites this paper
• Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority

  2019cites this paper
• Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology

  2019influential citation
• Quantitative Comparison of the Efficacies of 5 First‐Line Drugs for Primary Restless Leg Syndrome

  2019cites this paper
• Modelling time‐course relationships with multiple treatments: Model‐based network meta‐analysis for continuous summary outcomes

  2019cites this paper
• Model‐Based Meta‐Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence

  2019cites this paper
• Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

  2018cites this paper
• Many Flavors of Model‐Based Meta‐Analysis: Part II – Modeling Summary Level Longitudinal Responses

  2018cites this paper